116 related articles for article (PubMed ID: 36435059)
1. Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model.
Khaki Bakhtiarvand V; Ramezani-Ali Akbari K; Amir Jalali S; Hojjat-Farsangi M; Jeddi-Tehrani M; Shokri F; Shabani M
Int Immunopharmacol; 2022 Dec; 113(Pt B):109470. PubMed ID: 36435059
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b
Ramezani-Aliakbari K; Khaki-Bakhtiarvand V; Mahmoudian J; Asgarian-Omran H; Shokri F; Hojjat-Farsangi M; Jeddi-Tehrani M; Shabani M
Int Immunopharmacol; 2023 Aug; 121():110463. PubMed ID: 37327513
[TBL] [Abstract][Full Text] [Related]
3. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
4. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
5. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
6. Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model.
Balog JÁ; Hackler L; Kovács AK; Neuperger P; Alföldi R; Nagy LI; Puskás LG; Szebeni GJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881770
[TBL] [Abstract][Full Text] [Related]
7. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
8. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
11. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
12. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.
Özverel CS; Uyanikgil Y; Karaboz İ; Nalbantsoy A
Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):346-357. PubMed ID: 32515626
[TBL] [Abstract][Full Text] [Related]
14. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer.
Navashenaq JG; Zamani P; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Nanomedicine; 2020 Feb; 24():102150. PubMed ID: 31931230
[TBL] [Abstract][Full Text] [Related]
15. Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer.
Forghani P; Waller EK
Breast Cancer Res Treat; 2015 Aug; 153(1):21-30. PubMed ID: 26208484
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
[TBL] [Abstract][Full Text] [Related]
17. T
Rasé VJ; Hayward R; Haughian JM; Pullen NA
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142210
[TBL] [Abstract][Full Text] [Related]
18. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
19. Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
Sierra RA; Trillo-Tinoco J; Mohamed E; Yu L; Achyut BR; Arbab A; Bradford JW; Osborne BA; Miele L; Rodriguez PC
Cancer Res; 2017 Oct; 77(20):5628-5638. PubMed ID: 28904063
[TBL] [Abstract][Full Text] [Related]
20. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]